Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.23
NAS:CLVS's Cash-to-Debt is ranked lower than
69% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:CLVS: 2.23 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CLVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91  Med: 5001.19 Max: No Debt
Current: 2.23
Equity-to-Asset 0.37
NAS:CLVS's Equity-to-Asset is ranked lower than
76% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:CLVS: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CLVS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.37 Max: 0.75
Current: 0.37
-0.01
0.75
Debt-to-Equity 0.94
NAS:CLVS's Debt-to-Equity is ranked lower than
79% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:CLVS: 0.94 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:CLVS' s Debt-to-Equity Range Over the Past 10 Years
Min: -77.36  Med: 0.94 Max: 4.92
Current: 0.94
-77.36
4.92
Debt-to-EBITDA -0.80
NAS:CLVS's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:CLVS: -0.80 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:CLVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.8  Med: -0.76 Max: -0.75
Current: -0.8
-1.8
-0.75
Piotroski F-Score: 2
Altman Z-Score: 0.60
Beneish M-Score: 1.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -626.64
NAS:CLVS's Operating Margin % is ranked lower than
78% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:CLVS: -626.64 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CLVS' s Operating Margin % Range Over the Past 10 Years
Min: -477862.82  Med: -239512.91 Max: -626.64
Current: -626.64
-477862.82
-626.64
Net Margin % -947.47
NAS:CLVS's Net Margin % is ranked lower than
82% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:CLVS: -947.47 )
Ranked among companies with meaningful Net Margin % only.
NAS:CLVS' s Net Margin % Range Over the Past 10 Years
Min: -447611.54  Med: -224393.04 Max: -947.47
Current: -947.47
-447611.54
-947.47
ROE % -209.77
NAS:CLVS's ROE % is ranked lower than
93% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:CLVS: -209.77 )
Ranked among companies with meaningful ROE % only.
NAS:CLVS' s ROE % Range Over the Past 10 Years
Min: -235.1  Med: -83.7 Max: -26.78
Current: -209.77
-235.1
-26.78
ROA % -61.80
NAS:CLVS's ROA % is ranked lower than
76% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:CLVS: -61.80 )
Ranked among companies with meaningful ROA % only.
NAS:CLVS' s ROA % Range Over the Past 10 Years
Min: -144.39  Med: -51.12 Max: -21.25
Current: -61.8
-144.39
-21.25
ROC (Joel Greenblatt) % -8251.62
NAS:CLVS's ROC (Joel Greenblatt) % is ranked lower than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:CLVS: -8251.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CLVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9748.56  Med: -7941.19 Max: -3834.63
Current: -8251.62
-9748.56
-3834.63
3-Year EBITDA Growth Rate 48.70
NAS:CLVS's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:CLVS: 48.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CLVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.4  Med: 8.65 Max: 51.8
Current: 48.7
-53.4
51.8
3-Year EPS without NRI Growth Rate 45.40
NAS:CLVS's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:CLVS: 45.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CLVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.1  Med: 7.15 Max: 48.8
Current: 45.4
-53.1
48.8
GuruFocus has detected 4 Warning Signs with Clovis Oncology Inc NAS:CLVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CLVS's 30-Y Financials

Financials (Next Earnings Date: 2018-02-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CLVS Guru Trades in Q4 2016

John Burbank 381,814 sh (New)
Jim Simons 82,100 sh (New)
Chuck Royce 76,000 sh (New)
Columbia Wanger 189,958 sh (-6.88%)
» More
Q1 2017

CLVS Guru Trades in Q1 2017

Jim Simons 153,400 sh (+86.85%)
Chuck Royce 76,000 sh (unchged)
Columbia Wanger Sold Out
John Burbank 202,804 sh (-46.88%)
Louis Moore Bacon 40,000 sh (-57.89%)
» More
Q2 2017

CLVS Guru Trades in Q2 2017

Leon Cooperman 50,000 sh (New)
Ron Baron 15,015 sh (New)
Steven Cohen 30,000 sh (New)
Joel Greenblatt 3,727 sh (New)
Jim Simons 326,200 sh (+112.65%)
John Burbank Sold Out
Chuck Royce 66,000 sh (-13.16%)
Louis Moore Bacon 10,000 sh (-75.00%)
» More
Q3 2017

CLVS Guru Trades in Q3 2017

Ken Fisher 26,633 sh (New)
Columbia Wanger 581,660 sh (New)
Louis Moore Bacon 30,000 sh (+200.00%)
Ron Baron 29,147 sh (+94.12%)
Leon Cooperman Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Chuck Royce 50,000 sh (-24.24%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-09-30 Add 94.12%$67.17 - $98.02 $ 64.33-19%29,147
Ken Fisher 2017-09-30 New Buy$67.17 - $98.02 $ 64.33-19%26,633
Leon Cooperman 2017-09-30 Sold Out 0.2%$67.17 - $98.02 $ 64.33-19%0
Joel Greenblatt 2017-09-30 Sold Out $67.17 - $98.02 $ 64.33-19%0
Leon Cooperman 2017-06-30 New Buy0.2%$45.93 - $96.78 $ 64.336%50,000
Ron Baron 2017-06-30 New Buy0.01%$45.93 - $96.78 $ 64.336%15,015
Joel Greenblatt 2017-06-30 New Buy$45.93 - $96.78 $ 64.336%3,727
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SHSE:600201, TSE:4587, LSE:BTG, NAS:NKTR, XSWX:BION, NAS:FGEN, SHSE:600161, OSTO:SOBI, XKRX:215600, SZSE:002007, SZSE:000990, NAS:AVXS, BOM:532523, NAS:BGNE, NAS:ACAD, NAS:AAAP, SZSE:000661, SZSE:002603, NAS:AGIO, NAS:ONCE » details
Traded in other countries:C6O.Germany,
Headquarter Location:USA
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

Ratios

vs
industry
vs
history
PB Ratio 10.53
CLVS's PB Ratio is ranked lower than
85% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CLVS: 10.53 )
Ranked among companies with meaningful PB Ratio only.
CLVS' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 5.23 Max: 18.33
Current: 10.53
1.28
18.33
PS Ratio 77.51
CLVS's PS Ratio is ranked lower than
90% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CLVS: 77.51 )
Ranked among companies with meaningful PS Ratio only.
CLVS' s PS Ratio Range Over the Past 10 Years
Min: 31.02  Med: 136.15 Max: 32900
Current: 77.51
31.02
32900
EV-to-EBIT -8.12
CLVS's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CLVS: -8.12 )
Ranked among companies with meaningful EV-to-EBIT only.
CLVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -26  Med: -9.3 Max: -1.4
Current: -8.12
-26
-1.4
EV-to-EBITDA -8.17
CLVS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CLVS: -8.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27  Med: -9.6 Max: -1.5
Current: -8.17
-27
-1.5
EV-to-Revenue 75.06
CLVS's EV-to-Revenue is ranked lower than
85% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CLVS: 75.06 )
Ranked among companies with meaningful EV-to-Revenue only.
CLVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 16.2  Med: 115.25 Max: 32775.2
Current: 75.06
16.2
32775.2
Current Ratio 3.19
CLVS's Current Ratio is ranked lower than
58% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CLVS: 3.19 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 8.02 Max: 31.09
Current: 3.19
0.86
31.09
Quick Ratio 3.16
CLVS's Quick Ratio is ranked lower than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CLVS: 3.16 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 8.02 Max: 31.09
Current: 3.16
0.86
31.09
Days Inventory 165.07
CLVS's Days Inventory is ranked lower than
71% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. CLVS: 165.07 )
Ranked among companies with meaningful Days Inventory only.
CLVS' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 165.07
Current: 165.07
0
165.07
Days Sales Outstanding 249.38
CLVS's Days Sales Outstanding is ranked higher than
86% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CLVS: 249.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.86  Med: 313.54 Max: 566.22
Current: 249.38
60.86
566.22
Days Payable 644.35
CLVS's Days Payable is ranked lower than
97% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. CLVS: 644.35 )
Ranked among companies with meaningful Days Payable only.
CLVS' s Days Payable Range Over the Past 10 Years
Min: 644.35  Med: 56898.29 Max: 56898.29
Current: 644.35
644.35
56898.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
CLVS's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CLVS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.2 Max: -4.5
Current: -4.5
-194.7
-4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 25.84
CLVS's Price-to-Net-Cash is ranked lower than
81% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CLVS: 25.84 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CLVS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.45  Med: 12.03 Max: 61.22
Current: 25.84
2.45
61.22
Price-to-Net-Current-Asset-Value 16.37
CLVS's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CLVS: 16.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CLVS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 11.53 Max: 43.02
Current: 16.37
2.43
43.02
Price-to-Tangible-Book 14.65
CLVS's Price-to-Tangible-Book is ranked lower than
84% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CLVS: 14.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CLVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.39  Med: 10.97 Max: 396.95
Current: 14.65
2.39
396.95
Price-to-Median-PS-Value 0.57
CLVS's Price-to-Median-PS-Value is ranked lower than
66% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CLVS: 0.57 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CLVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.14 Max: 164.52
Current: 0.57
0.56
164.52
Earnings Yield (Greenblatt) % -12.31
CLVS's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CLVS: -12.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -70.4  Med: -10.7 Max: -3.9
Current: -12.31
-70.4
-3.9

More Statistics

Revenue (TTM) (Mil) $38.55
EPS (TTM) $ -8.28
Beta1.32
Short Percentage of Float16.84%
52-Week Range $33.23 - 99.45
Shares Outstanding (Mil)50.35

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 61 219 450 669
EPS ($) -7.67 -3.12 0.34 2.69
EPS without NRI ($) -7.67 -3.12 0.34 2.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}